Phase 3 N=389 Study of Pyridoxine for Hand-Foot Syndrome
Hand-foot Syndrome
Primary: Cumulative Dose of Capecitabine Until the Development of Grade 2 or Higher Hand-foot Syndrome — 70000; 70000 miligram per square meter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=137 Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
Breast Cancer · Drug/Agent Toxicity by Tissue/Organ · Unspecified Adult Solid Tumor, Protocol Specific
Primary: To Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream Can Decrease the Incidence/Severity of Capecitabine-caused Palmar-plantar…
Phase 3 N=34 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
Breast Cancer · Drug/Agent Toxicity by Tissue/Organ · Endometrial Cancer
Primary: Number of Participants With Palmar-plantar Erythrodysesthesia (PPE) — 2; 3; 3; 3 participants — p=<0.05
Phase 3 N=195 Standard Versus Continuous Capecitabine in Advanced Breast Cancer
Metastatic Breast Cancer
Primary: Time to Progression — 8.68; 6.84 months — p=0.1224
N/A N=111 Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment
Metastatic Renal Cell Carcinoma
Primary: Number of Participants Categorized According to the Napping Habits for All Participants at Baseline — 22; 33; 31 Participants
N/A N=27 Hands on - a Hand Care Guide in Systemic Sclerosis
Scleroderma
Primary: Cochin Hand Functional Scale — 19.24 units on a scale
Phase 2 N=95 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Metastatic Colorectal Cancer · Skin Rash · Skin Toxicities
Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants
Phase 2 N=12 Phase II Study of Perindopril and Regorafenib in mCRC
Metastatic Colorectal Cancer
Primary: Number of Participants That Have Any Grade HFSR Toxicity — 7 Participants
Phase 1 N=15 Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
Pachyonychia Congenita
Primary: Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels — 15; 15; 15; 14 participants
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
N/A N=280 Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose
Breast Neoplasms
Primary: Evaluation of the Occurrence of Nail Toxicity of Grade 2 of Common Toxicity Criteria for Adverse Effects V4.0 Evaluated at 8 Weeks Post Infusion of Docetaxel. — 26; 49…
N/A N=224 Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)
Ovarian Neoplasms
Primary: Occurrences of Infusion Reactions and Palmar-Plantar Erythrodysesthesia (PPE) — 2; 5; 2; 1 Events
N/A N=154 A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)
Ovarian Neoplasms · Breast Neoplasms · Paresthesia
Primary: Number of Participants Who Received Concomitant Treatment Strategies to Manage Palmar-Plantar Erythrodysesthesia (PPE) — 10; 8; 8; 3 Participants
N/A N=42 Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome
Breast Carcinoma
Primary: Area Under the Curve (AUC) EORTC CIPN20 Sensory Neuropathy Subscale Adjusting for Baseline — -1.4; -4.4 Average(subscale value*assessment) — p=0.26
N/A N=20 Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
Ischemia
Primary: Digital Micro-vascular Flow — .11; .18; -.01; -.06 perfusion unit
Phase 3 N=133 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
Moderate to Severe Atopic Hand and Foot Dermatitis
Primary: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 — 16.7; 40.3 Percentage of participants — p==0.0030
N/A N=94 Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients
Breast Carcinoma
Primary: Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) — 41; 30; 25 Participants
Phase 4 N=72 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
Psoriasis
Primary: Number of Subjects With Physician's Global Assessment of Psoriasis (PGA) of Clear or Almost Clear at Week 16 — 1; 15 subjects — p=0.014
Phase 4 N=20 A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis
Hand Dermatitis
Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale
Phase 2 N=8 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
Phase 2 N=64 Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia · Advanced Myelodysplastic Syndromes
Primary: To Reduce the Early Transplant-related Mortality.
N/A N=12 Breast/Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy
Peripheral Neuropathies
Primary: Prevention of Peripheral Neuropathy During Taxane Chemotherapy — 7.28 score on a scale
Phase 2 N=20 Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
Psoriasis
Primary: The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks. — 8; 12 participants
Phase 2 N=8 Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis Bullosa Simplex · Epidermolysis Bullosa Simplex Kobner · Weber-Cockayne Syndrome
Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale
Phase 2 N=123 Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Colon Adenocarcinoma · Rectal Adenocarcinoma · Stage III Colorectal Cancer AJCC v7
Primary: Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3 — 0.43; 0.26 proportion of patients — p=0.0434
Phase 2 N=9 Imatinib in Systemic Sclerosis
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
N/A N=32 Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Toxicities
Primary: Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) — 2.70; 2.41; 2.70; 2.29 units on a scale
Phase 3 N=41 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Scleroderma, Systemic · Scleroderma, Diffuse · Scleroderma, Limited
Primary: Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) Before Cold Stimulus — 260.0; 246.3 perfusion units
Phase 2 N=30 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
Systemic Sclerosis
Primary: Improvement in the Modified Rodnan Skin Score — -6.6 units on a scale
Phase 2 N=12 Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
Systemic Sclerosis · Calcinosis
Primary: Number of Participants With Treatment-related Adverse Events Following Treatment With Oral Treprostinil — 11 Participants